胃不全麻痺治療薬の世界市場レポート 2025年

胃不全麻痺治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.9％で72億米ドルに成長します。予測期間の成長は、糖尿病有病率の増加、高齢化、認知度・診断率の上昇、ヘルスケア支出の増加、政府・民間資金の投入などに起因すると考えられます。予測期間における主な動向には、消化器病学の進歩、診断技術の向上、技術革新、研究資金、共同研究への取り組みなどがあります。

糖尿病有病率の増加が胃不全麻痺治療薬市場の拡大を牽引すると予想されます。糖尿病は、インスリン分泌不足またはインスリンを効果的に使用できない体質による血糖値上昇を特徴とする慢性疾患です。糖尿病患者の増加は、座りがちなライフスタイル、食生活の乱れ、遺伝的素因、都市化、高齢化、ヘルスケアへのアクセス制限、世界の肥満率の増加などの要因に起因しています。胃不全麻痺治療薬は、吐き気、嘔吐、胃排出遅延などの症状を緩和するために糖尿病患者に処方されるのが一般的です。これらの薬剤は、胃の運動を改善し、糖尿病に関連した胃不全麻痺患者の生活の質を高めることを目的としています。例えば、2024年3月、英国の政府部門であるOffice for Health Improvement &Disparitiesによると、2022年3月から2023年3月の間に、推奨される8つのケアプロセスをすべて受けている1型糖尿病患者の割合は22％増加し、2型糖尿病患者の割合は21％増加しました。さらに、HbA1cの目標値を達成した人の割合は37.9%に上昇し、全国糖尿病監査（NDA）が報告した中で過去最高となりました。したがって、糖尿病有病率の上昇が胃不全麻痺治療薬市場の成長に寄与しています。

胃不全麻痺治療薬分野の主要企業は、市場競争力を強化するため、Gimoti（メトクロプラミド）点鼻スプレーのような革新的な医薬品の導入に力を注いでいます。Gimoti（メトクロプラミド）点鼻スプレーは、成人の胃不全麻痺の症状を緩和するために設計された医薬品で、消化管運動を強化することにより胃の空洞化を促進します。消化管を経由しないため、鼻粘膜から直接血流に吸収されます。例えば、2022年4月、米国の製薬会社Evoke Pharma Inc.は、米国食品医薬品局（FDA）がGIMOTI（メトクロプラミド）点鼻スプレーの新薬独占権を付与したことを明らかにしました。この独占権は、ハッチ・ワックスマン法（Hatch-Waxman Act）に基づき、最初の承認日から3年間、Evoke社に独占販売権を与えるもので、同製品をジェネリック医薬品との競合から保護するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界胃不全麻痺治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の胃不全麻痺治療薬市場：成長率分析
• 世界の胃不全麻痺治療薬市場の実績：規模と成長, 2019-2024
• 世界の胃不全麻痺治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界胃不全麻痺治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の胃不全麻痺治療薬市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 市販薬（OTC）
• 処方薬
• 世界の胃不全麻痺治療薬市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 糖尿病性胃不全麻痺
• 術後胃不全麻痺
• 特発性胃不全麻痺
• その他の病気の種類
• 世界の胃不全麻痺治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• その他の投与経路
• 世界の胃不全麻痺治療薬市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 消化管運動促進剤
• 制吐薬
• プロトンポンプ阻害剤
• その他の薬物クラス
• 世界の胃不全麻痺治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 薬局
• クリニック
• eコマース
• 世界の胃不全麻痺治療薬市場市販薬（OTC）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 制酸剤
• 吐き気止め薬
• 制吐剤
• 消化酵素サプリメント
• 世界の胃不全麻痺治療薬市場処方薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 消化管運動促進剤
• 制吐薬
• 抗生物質
• 抗うつ薬

第7章 地域別・国別分析

• 世界の胃不全麻痺治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の胃不全麻痺治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 胃不全麻痺治療薬市場：競合情勢
• 胃不全麻痺治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Abbott Laboratories
• GSK plc
• Takeda Pharmaceutical Inc.
• Teva Pharmaceutical Inc.
• Otsuka Pharmaceutical Co. Ltd.
• Bausch Health Companies Inc.
• Eisai Co. Ltd.
• Evoke Pharma Inc.
• Cadila Pharmaceuticals
• Cipla Ltd.
• Neurogastrx Inc.
• Ipca Laboratories Ltd.
• ANI Pharmaceuticals Inc.
• Salix Pharmaceuticals Inc.
• Vanda Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 胃不全麻痺治療薬市場2029：新たな機会を提供する国
• 胃不全麻痺治療薬市場2029：新たな機会を提供するセグメント
• 胃不全麻痺治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Gastroparesis drugs are medications utilized to handle and address gastroparesis, a condition characterized by delayed emptying of the stomach, leading to symptoms such as nausea, vomiting, and abdominal discomfort. Typically, these medications consist of prokinetics to enhance stomach motility, antiemetics to regulate nausea and vomiting, and drugs to alleviate pain and other associated symptoms.

The primary categories of gastroparesis drugs consist of over-the-counter (OTC) medications and prescription drugs. Over-the-counter (OTC) drugs are those available for purchase without a prescription from a healthcare provider. These medications are utilized for treating various forms of gastroparesis, including diabetic gastroparesis, post-surgical gastroparesis, idiopathic gastroparesis, among others, and are administered through various routes such as oral ingestion, injection, and others. They encompass various types of drugs such as prokinetic agents, antiemetics, proton pump inhibitors, among others, which are distributed through hospitals, pharmacies, clinics, and online platforms.

The gastroparesis drugs market research report is one of a series of new reports from The Business Research Company that provides gastroparesis drugs market statistics, including gastroparesis drugs industry global market size, regional shares, competitors with a gastroparesis drugs market share, detailed gastroparesis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gastroparesis drugs industry. This gastroparesis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastroparesis drugs market size has grown strongly in recent years. It will grow from $5.39 billion in 2024 to $5.73 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to side effects of existing treatments, gastrointestinal motility research, clinical need, patient advocacy, and regulatory support.

The gastroparesis drugs market size is expected to see strong growth in the next few years. It will grow to $7.2 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to the increasing prevalence of diabetes, the aging population, rising awareness and diagnosis rates, increase in healthcare expenditure, and government and private funding. Major trends in the forecast period include advancements in gastroenterology, improved diagnostic techniques, technological innovations, research funding, and collaborative research efforts.

The growing prevalence of diabetes is expected to drive the expansion of the gastroparesis drugs market. Diabetes is a chronic condition characterized by elevated blood sugar levels due to insufficient insulin production or the body's inability to effectively use insulin. The rise in diabetes cases is attributed to factors such as sedentary lifestyles, poor dietary habits, genetic predisposition, urbanization, aging populations, limited healthcare access, and increasing obesity rates globally. Gastroparesis drugs are commonly prescribed to diabetic patients to alleviate symptoms such as nausea, vomiting, and delayed gastric emptying-gastrointestinal issues that are frequent complications of diabetes. These medications aim to improve gastric motility and enhance the quality of life for those with diabetes-related gastroparesis. For example, in March 2024, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, the increase was 21%. Additionally, the percentage of individuals achieving target HbA1c levels rose to 37.9%, the highest ever reported by the National Diabetes Audit (NDA). Therefore, the rising prevalence of diabetes is contributing to the growth of the gastroparesis drugs market.

Major players in the gastroparesis drugs sector are directing their efforts towards introducing innovative medications, such as the Gimoti (metoclopramide) nasal spray, to enhance their market competitiveness. Gimoti (metoclopramide) nasal spray is a pharmaceutical designed to alleviate symptoms of gastroparesis in adults, fostering stomach emptying by bolstering gastrointestinal motility. By circumventing the gastrointestinal tract, it is absorbed directly into the bloodstream via the nasal mucosa. For example, in April 2022, Evoke Pharma Inc., a pharmaceutical company based in the United States, disclosed that the U.S. Food and Drug Administration (FDA) had granted GIMOTI (metoclopramide) nasal spray new drug product exclusivity. This exclusivity affords Evoke exclusive marketing privileges for three years following the initial approval date, as per the Hatch-Waxman Act, shielding the product from generic competition.

In June 2022, Eagle Pharmaceuticals Inc., a pharmaceutical firm headquartered in the United States, completed the acquisition of Acacia Pharma Group plc for $102 million (€94.7 million). Through this acquisition, Eagle Pharmaceuticals intends to broaden its range of offerings by integrating Acacia's FDA-approved hospital products, BARHEMSYS and BYFAVO, which cater to unmet clinical demands in acute care environments. Acacia Pharma Group plc, based in the United Kingdom, specializes in providing antiemetic medications utilized in gastroparesis treatment.

Major companies operating in the gastroparesis drugs market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Inc., Teva Pharmaceutical Inc., Otsuka Pharmaceutical Co. Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Evoke Pharma Inc., Cadila Pharmaceuticals, Cipla Ltd., Neurogastrx Inc., Ipca Laboratories Ltd., ANI Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc, Rhythm Pharmaceuticals Inc., Processa Pharmaceuticals Inc., Aclipse Therapeutics LLC, ETX Pharma Inc.

North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastroparesis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The gastroparesis drugs market consists of sales of ondansetron, metoclopramide, amitriptyline, and erythromycin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastroparesis Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastroparesis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastroparesis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastroparesis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Over-the-counter (OTC) Drugs; Prescription Drugs
• 2) By Drug Class: Prokinetic Agents; Antiemetic Drugs; Proton Pump Inhibitors; Other Drug Classes
• 3) By Disease Type: Diabetic Gastroparesis; Post-Surgical Gastroparesis; Idiopathic Gastroparesis; Other Disease Types
• 4) By Route Of Administration: Oral; Injectables; Other Routes Of Administration
• 5) By Distribution Channel: Hospitals; Pharmacies; Clinics; E-commerce
• Subsegments:
• 1) Over-the-counter (OTC) Drugs: Antacids; Anti-Nausea Medications; Antiemetics; Digestive Enzyme Supplements
• 2) Prescription Drugs: Prokinetic Agents; Antiemetic Drugs; Antibiotics; Antidepressants
• Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Bayer AG; Sanofi SA.; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gastroparesis Drugs Market Characteristics

3. Gastroparesis Drugs Market Trends And Strategies

4. Gastroparesis Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Gastroparesis Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gastroparesis Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gastroparesis Drugs Market Growth Rate Analysis
• 5.4. Global Gastroparesis Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gastroparesis Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gastroparesis Drugs Total Addressable Market (TAM)

6. Gastroparesis Drugs Market Segmentation

• 6.1. Global Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Over-The-Counter (OTC) Drugs
• Prescription Drugs
• 6.2. Global Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diabetic Gastroparesis
• Post-Surgical Gastroparesis
• Idiopathic Gastroparesis
• Other Disease Types
• 6.3. Global Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectables
• Other Routes Of Administration
• 6.4. Global Gastroparesis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prokinetic Agents
• Antiemetic Drugs
• Proton Pump Inhibitors
• Other Drug Classes
• 6.5. Global Gastroparesis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Pharmacies
• Clinics
• E-commerce
• 6.6. Global Gastroparesis Drugs Market, Sub-Segmentation Of Over-the-counter (OTC) Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antacids
• Anti-Nausea Medications
• Antiemetics
• Digestive Enzyme Supplements
• 6.7. Global Gastroparesis Drugs Market, Sub-Segmentation Of Prescription Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prokinetic Agents
• Antiemetic Drugs
• Antibiotics
• Antidepressants

7. Gastroparesis Drugs Market Regional And Country Analysis

• 7.1. Global Gastroparesis Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gastroparesis Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gastroparesis Drugs Market

• 8.1. Asia-Pacific Gastroparesis Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gastroparesis Drugs Market

• 9.1. China Gastroparesis Drugs Market Overview
• 9.2. China Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gastroparesis Drugs Market

• 10.1. India Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gastroparesis Drugs Market

• 11.1. Japan Gastroparesis Drugs Market Overview
• 11.2. Japan Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gastroparesis Drugs Market

• 12.1. Australia Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gastroparesis Drugs Market

• 13.1. Indonesia Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gastroparesis Drugs Market

• 14.1. South Korea Gastroparesis Drugs Market Overview
• 14.2. South Korea Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gastroparesis Drugs Market

• 15.1. Western Europe Gastroparesis Drugs Market Overview
• 15.2. Western Europe Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gastroparesis Drugs Market

• 16.1. UK Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gastroparesis Drugs Market

• 17.1. Germany Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gastroparesis Drugs Market

• 18.1. France Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gastroparesis Drugs Market

• 19.1. Italy Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gastroparesis Drugs Market

• 20.1. Spain Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gastroparesis Drugs Market

• 21.1. Eastern Europe Gastroparesis Drugs Market Overview
• 21.2. Eastern Europe Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gastroparesis Drugs Market

• 22.1. Russia Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gastroparesis Drugs Market

• 23.1. North America Gastroparesis Drugs Market Overview
• 23.2. North America Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gastroparesis Drugs Market

• 24.1. USA Gastroparesis Drugs Market Overview
• 24.2. USA Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gastroparesis Drugs Market

• 25.1. Canada Gastroparesis Drugs Market Overview
• 25.2. Canada Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gastroparesis Drugs Market

• 26.1. South America Gastroparesis Drugs Market Overview
• 26.2. South America Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gastroparesis Drugs Market

• 27.1. Brazil Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gastroparesis Drugs Market

• 28.1. Middle East Gastroparesis Drugs Market Overview
• 28.2. Middle East Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gastroparesis Drugs Market

• 29.1. Africa Gastroparesis Drugs Market Overview
• 29.2. Africa Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gastroparesis Drugs Market Competitive Landscape And Company Profiles

• 30.1. Gastroparesis Drugs Market Competitive Landscape
• 30.2. Gastroparesis Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi SA. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Gastroparesis Drugs Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. GSK plc
• 31.3. Takeda Pharmaceutical Inc.
• 31.4. Teva Pharmaceutical Inc.
• 31.5. Otsuka Pharmaceutical Co. Ltd.
• 31.6. Bausch Health Companies Inc.
• 31.7. Eisai Co. Ltd.
• 31.8. Evoke Pharma Inc.
• 31.9. Cadila Pharmaceuticals
• 31.10. Cipla Ltd.
• 31.11. Neurogastrx Inc.
• 31.12. Ipca Laboratories Ltd.
• 31.13. ANI Pharmaceuticals Inc.
• 31.14. Salix Pharmaceuticals Inc.
• 31.15. Vanda Pharmaceuticals Inc.

32. Global Gastroparesis Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gastroparesis Drugs Market

34. Recent Developments In The Gastroparesis Drugs Market

35. Gastroparesis Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Gastroparesis Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gastroparesis Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gastroparesis Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer